share_log

AHN Cancer Institute To Offer Groundbreaking Treatment For Metastatic Melanoma; The One-Time Treatment, Made By Iovance Biotherapeutics, Is The First FDA-Approved T-Cell Therapy For Solid Tumors

AHN Cancer Institute To Offer Groundbreaking Treatment For Metastatic Melanoma; The One-Time Treatment, Made By Iovance Biotherapeutics, Is The First FDA-Approved T-Cell Therapy For Solid Tumors

AHN癌症研究所將爲轉移性黑色素瘤提供開創性的治療方法；由Iovance Biotherapeutics開發的一次性治療是美國食品藥品管理局批准的首種實體瘤T細胞療法
Benzinga ·  04/22 20:49
Allegheny Health Network (AHN) Cancer Institute has become the first health care system in Western Pennsylvania to offer a first-of-its-kind cellular therapy recently approved by the U.S. Food and Drug Administration to treat metastatic melanoma.
阿勒格尼健康網絡（AHN）癌症研究所已成爲賓夕法尼亞州西部第一個提供同類細胞療法的醫療保健系統，該療法最近獲得美國食品藥品監督管理局的批准，用於治療轉移性黑色素瘤。
Amtagvi provides new hope for adult patients with hard-to-treat melanoma. This includes patients who haven't had success with other medications, have skin cancer that can't be removed through surgery (unresectable), or have skin cancer that has spread throughout the body (metastatic).
Amtagvi爲難以治療的黑色素瘤的成年患者提供了新的希望。這包括未成功使用其他藥物的患者、患有無法通過手術切除（不可切除的）皮膚癌或皮膚癌已擴散到全身（轉移性）的患者。
The one-time treatment, made by Iovance Biotherapeutics, is the first FDA-approved T-cell therapy...
這種一次性療法由Iovance ...
登入免費觀看全文
登入/註冊

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論